Comments on Best Practices in Developing Proprietary Names for Human Nonprescription Drugs

Share page:
Docket Number:
FDA-2020-D-0770

In keeping with the mission of the FDA Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology Division of Medication Error and Prevention Analysis, this CHPA member feedback is designed to minimize the risk of medication errors due to consumer confusion attributed to an OTC drug product name.